We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Moves -0.29%: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed the most recent trading day at $44.37, moving -0.29% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.43%. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq added 0.26%.
Coming into today, shares of the drugmaker had gained 1.71% in the past month. In that same time, the Medical sector lost 4.49%, while the S&P 500 lost 4.68%.
Investors will be hoping for strength from PFE as it approaches its next earnings release, which is expected to be October 30, 2018. On that day, PFE is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 13.43%. Our most recent consensus estimate is calling for quarterly revenue of $13.30 billion, up 1.03% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.99 per share and revenue of $53.84 billion. These results would represent year-over-year changes of +12.83% and +2.47%, respectively.
It is also important to note the recent changes to analyst estimates for PFE. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. PFE currently has a Zacks Rank of #3 (Hold).
Digging into valuation, PFE currently has a Forward P/E ratio of 14.9. This represents a discount compared to its industry's average Forward P/E of 15.88.
It is also worth noting that PFE currently has a PEG ratio of 2.28. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 47, which puts it in the top 18% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Moves -0.29%: What You Should Know
Pfizer (PFE - Free Report) closed the most recent trading day at $44.37, moving -0.29% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.43%. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq added 0.26%.
Coming into today, shares of the drugmaker had gained 1.71% in the past month. In that same time, the Medical sector lost 4.49%, while the S&P 500 lost 4.68%.
Investors will be hoping for strength from PFE as it approaches its next earnings release, which is expected to be October 30, 2018. On that day, PFE is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 13.43%. Our most recent consensus estimate is calling for quarterly revenue of $13.30 billion, up 1.03% from the year-ago period.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.99 per share and revenue of $53.84 billion. These results would represent year-over-year changes of +12.83% and +2.47%, respectively.
It is also important to note the recent changes to analyst estimates for PFE. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.14% lower. PFE currently has a Zacks Rank of #3 (Hold).
Digging into valuation, PFE currently has a Forward P/E ratio of 14.9. This represents a discount compared to its industry's average Forward P/E of 15.88.
It is also worth noting that PFE currently has a PEG ratio of 2.28. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.05 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 47, which puts it in the top 18% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.